Latest News
Friday May 23, 2008 — AstraZeneca
WILMINGTON, Del., May 22 /PRNewswire-FirstCall/ -- AstraZeneca announced today that it supports the revised Physician Payment Sunshine Act as part of the company's latest step to provide the public with more information about the way it does business.Sponsored by Sens. Charles Grassley of Iowa a...
Wednesday May 21, 2008 — AstraZeneca
WILMINGTON, Del., May 20 /PRNewswire-FirstCall/ -- A new 12-week study(2) examined safety and efficacy measures of the maintenance combination asthma therapy, SYMBICORT(R) (budesonide/formoterol fumarate dehydrate) Inhalation Aerosol(2) in treating mild to moderate persistent asthma in children a...
Tuesday May 20, 2008 — AstraZeneca
WILMINGTON, Del., May 20 /PRNewswire-FirstCall/ -- A new open-label study evaluated patient satisfaction with budesonide/formoterol combination therapy and fluticasone/salmeterol combination therapy, as measured by the Asthma Treatment Satisfaction Measure (ATSM)(1). Patients participating in the...
Monday May 19, 2008 — AstraZeneca
WILMINGTON, Del., May 19 /PRNewswire-FirstCall/ -- Over the last three years, Hispanic-Americans have become increasingly aware of a potentially serious condition called Gastroesophageal Reflux Disease (GERD), also known as Acid Reflux Disease. Approximately 6.1 million Hispanics in the United S...
Friday May 16, 2008 — MedImmune
GAITHERSBURG, Md., May 15 /PRNewswire/ -- MedImmune today announced that researchers will present eight abstracts from its respiratory disease program at the Annual Meeting of the American Thoracic Society, from May 18 to 20, 2008 in Toronto, Canada. Presentations are designed to showcase MedImmu...
Wednesday May 14, 2008 — AstraZeneca
WILMINGTON, Del., May 14 /PRNewswire-FirstCall/ -- AstraZeneca today announced that the U.S. Food and Drug Administration (FDA) has approved SEROQUEL(R) (quetiapine fumarate tablets) for the maintenance treatment of patients with bipolar I disorder, as adjunct therapy to lithium or divalproex. S...
Thursday May 8, 2008 — AstraZeneca
WILMINGTON, Del., May 8 /PRNewswire-FirstCall/ -- AstraZeneca today announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for SEROQUEL XR(TM) (quetiapine fumarate) Extended-Release Tablets to seek approval for the treatment of gener...
Tuesday May 6, 2008 — MedImmune
GAITHERSBURG, Md., May 6 /PRNewswire/ -- MedImmune today announced that it has enhanced its leadership team to guide the company's expanded product pipeline in the United States and abroad as well as the core scientific research that underpins this development. Jacqueline Hall has been appointed ...
Tuesday May 6, 2008 — PR Newswire
WASHINGTON, DC, May 6 /CNW/ -- - International Reach of 'Young Minds in Psychiatry' Awards is BoostedWith Astrazeneca Support -WASHINGTON, DC, May 6 /CNW/ - For the first time, a researcher from China has received one of the American Psychiatric Association's (APA) prestigious "Young Minds in Psyc...
Tuesday May 6, 2008 — AstraZeneca
WASHINGTON, DC, May 6 /PRNewswire-FirstCall/ -- - International Reach of 'Young Minds in Psychiatry' Awards is Boosted With AstraZeneca SupportFor the first time, a researcher from China has received one of the American Psychiatric Association's (APA) prestigious "Young Minds in Psychiatry" award...
Tuesday May 6, 2008 — AstraZeneca
WILMINGTON, Del., May 5 /PRNewswire-FirstCall/ -- AstraZeneca today announced new study data on SEROQUEL XR(TM) (quetiapine fumarate) Extended-Release Tablets for the treatment of major depressive disorder (MDD) and generalized anxiety disorder (GAD) in adult patients. The results from the studi...
Tuesday May 6, 2008 — MedImmune
HONOLULU, May 5 /PRNewswire/ -- Research presented at the annual meeting of the Pediatric Academic Societies (PAS) shows that by starting flu vaccinations in August -- ahead of the start of the typical flu vaccination season -- healthcare providers could reach an additional 10.7 million children ...
Monday May 5, 2008 — MedImmune
HONOLULU, May 5 /PRNewswire/ -- Data from two new studies presented at the annual meeting of the Pediatric Academic Societies (PAS) demonstrate that FluMist(R) (Influenza Virus Vaccine Live, Intranasal) may offer children both durable protection against influenza, as well as significant protectio...
Monday May 5, 2008 — PR Newswire
HONOLULU, May 5 /CNW/ --
Retrospective Chart Review in 10 Geographic Regions throughout the United
States Presented at Pediatric Academic Societies (PAS) Annual Meeting
MedImmune announced today that the company presented results from a retrospective chart review that evaluated ...
Monday May 5, 2008 — MedImmune
HONOLULU, May 5 /PRNewswire/ -- MedImmune announced today that the company presented results from a retrospective chart review that evaluated the use of Synagis(R) (palivizumab) as a preventive measure against respiratory syncytial virus (RSV) disease in high-risk infants. RSV is a leading cause...
Monday May 5, 2008 — PR Newswire
HONOLULU, May 4 /CNW/ --
- In Clinical Trial, Motavizumab Reduced Hospitalizations Due to
Respiratory Syncytial Virus by 83 Percent Compared to Placebo -
MedImmune today announced that researchers are currently presenting results from a MedImmune-sponsored Phase 3 study involvin...
Monday May 5, 2008 — MedImmune
HONOLULU, May 4 /PRNewswire/ -- MedImmune today announced that researchers are currently presenting results from a MedImmune-sponsored Phase 3 study involving motavizumab, an investigational monoclonal antibody (MAb) that is being evaluated for its potential to prevent serious disease caused by r...
Wednesday April 30, 2008 — AstraZeneca
WILMINGTON, Del., April 30 /PRNewswire-FirstCall/ -- AstraZeneca today announced that it submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for approval of a new indication for SYMBICORT(R) (budesonide/formoterol fumarate dihydrate) Inhalation Aer...
Tuesday April 29, 2008 — MedImmune
GAITHERSBURG, Md., April 28 /PRNewswire/ -- MedImmune today announced that researchers will present results from a host of studies in pediatric infectious disease, featuring FluMist(R) (Influenza Virus Vaccine Live, Intranasal) as well as Synagis(R) (palivizumab) and emerging RSV compounds motavi...
Thursday April 17, 2008 — AstraZeneca
ST. LOUIS, and WILMINGTON, Del., April 17 /PRNewswire-FirstCall/ -- Washington University School of Medicine in St. Louis and the pharmaceutical company AstraZeneca have announced a research collaboration that aims to develop new and improved ways to diagnose and treat Alzheimer's disease.The ma...
Tuesday April 15, 2008 — MedImmune
GAITHERSBURG, Md., April 15 /PRNewswire/ -- MedImmune today announced that it has advanced its efforts to develop CAT-354, a potential treatment for patients with asthma, with the start of two new trials with a monoclonal antibody (MAb) targeting interleukin-13 (IL-13). One of the studies is a Ph...
Thursday April 10, 2008 — MedImmune
SAN DIEGO, April 10 /PRNewswire/ -- MedImmune today announced that researchers will present seven abstracts on the company's oncology portfolio programs at the Annual Meeting of the American Association for Cancer Research, exemplifying the company's long-standing commitment to excellence in onco...
Friday March 28, 2008 — MedImmune
GAITHERSBURG, Md., March 27 /PRNewswire/ -- Local biotechnology leader MedImmune announced today that Seneca Valley High School student Yiwei Li has received the distinguished "MedImmune Advancing Science for Better Health" award for her ScienceMONTGOMERY project. The company sponsored the Montgo...
Wednesday March 26, 2008 — Zacks.com: Analyst Blog
AstraZeneca PLC (AZN) is engaged in the research, development, manufacturing and marketing of ethical (prescription) pharmaceutical products. The company ranks among the top pharmaceutical companies in the world based on revenues and global sales force. It is a leader in cardiovascular, c...
Wednesday March 19, 2008 — MedImmune
GAITHERSBURG, Md., March 18 /PRNewswire/ -- MedImmune today announced that its clinical program studying an investigational treatment targeting interleukin-9 (IL-9) has advanced with the start of a new trial in patients with asthma. The company initiated a Phase 2a clinical trial designed to asse...